|12 Months Ended|
Dec. 31, 2022
|Payables and Accruals [Abstract]|
Note 4 – Accounts Payable
Accounts payable consisted of the following (in thousands):
Schedule of Accounts Payable
The Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.
On October 5, 2020, the Company entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. The Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13.0 million. There was no outstanding liability with this third-party product manufacturer as of December 31, 2020.
During the year ended December 31, 2021, the Company recorded research and development expenses of $6.5 million related to the services rendered by this third-party product manufacturer and paid $142,500. In addition, the Company also issued shares of common stock with a fair value of $1.4 million pursuant to this Master Services Agreement. As of December 31, 2021, the outstanding balance due to this third-party product manufacturer amounted to $6.3 million.
On August 24, 2022, the Company entered into an agreement with this third-party manufacturer and issued 3.2 million as part of a payment agreement. The shares were valued at $ per share based on the closing price of the Company’s common stock on the date of the agreement. As part of the agreement, the Company also paid this third-party manufacturer $1.3 million on September 1, 2022, $1.0 million on October 3, 2022, and $1.0 million in November 2022. In addition, the Company and the third-party manufacturer agreed that services to be rendered in future periods, as specified in the agreement, will be paid or settled at the Company’s discretion, in a combination of cash and issuance of the Company’s common stock. The agreement also amended certain agreements executed in prior years which eliminated future financial commitments of the Company.shares of common stock with a fair value of $
During the year ended December 31, 2022, the Company recorded research and development expenses in the aggregate of $3.6 million for services rendered by this third-party product manufacturer and made additional payments of $900,000.
As of December 31, 2022, the Company was indebted $2.3 million to this third-party product manufacturer and was reported as part of accounts payable in the accompanying balance sheet.
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef